Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefotaxime sodium -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefotaxime sodium -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - cefotaxime sodium, quantity: 2097 mg (equivalent: cefotaxime, qty 2000 mg) - injection, powder for - excipient ingredients: - cefotaxime injection is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. infections of the respiratory tract (upper and lower). infections of the urinary tract. septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. intra-abdominal infection. gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of n. gonorrhoeae.) ear, nose and throat (ent) infections. skin and skin structure infections. bone and joint infections. meningitis - cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or penicillin g) for initial therapy in children, (excluding neonates), pending the availability of culture and sensitivity results. in adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. cefotaxime injection may be used for the prevention of post-operative infection in obstetric surgery, vaginal and abdominal hysterectomy and biliary surgery. in serious cases, cefotaxime injection may be used, if considered appropriate, before the results of sensitivity tests become available. the emergence of resistance to cefotaxime may complicate treatment.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - cefotaxime sodium, quantity: 1048 mg (equivalent: cefotaxime, qty 1000 mg) - injection, powder for - excipient ingredients: - cefotaxime injection is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. infections of the respiratory tract (upper and lower). infections of the urinary tract. septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. intra-abdominal infection. gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of n. gonorrhoeae.) ear, nose and throat (ent) infections. skin and skin structure infections. bone and joint infections. meningitis - cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or penicillin g) for initial therapy in children, (excluding neonates), pending the availability of culture and sensitivity results. in adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. cefotaxime injection may be used for the prevention of post-operative infection in obstetric surgery, vaginal and abdominal hysterectomy and biliary surgery. in serious cases, cefotaxime injection may be used, if considered appropriate, before the results of sensitivity tests become available. the emergence of resistance to cefotaxime may complicate treatment.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - cefotaxime sodium, quantity: 524 mg (equivalent: cefotaxime, qty 500 mg) - injection, powder for - excipient ingredients: - cefotaxime hexal injection is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. infections of the respiratory tract (upper and lower). infections of the urinary tract. septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. intra-abdominal infection. gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of n. gonorrhoeae.) ear, nose and throat (ent) infections. skin and skin structure infections. bone and joint infections. meningitis - cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or penicillin g) for initial therapy in children, (excluding neonates), pending the availability of culture and sensitivity results. in adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. cefotaxime hexal injection may be used for the prevention of post-operative infection in obstetric surgery, vaginal and abdominal hysterectomy and biliary surgery. in serious cases, cefotaxime hexal injection may be used, if considered appropriate, before the results of sensitivity tests become available. the emergence of resistance to cefotaxime may complicate treatment.

Namibie - angličtina - Namibia Medicines Regulatory Council

bodene (pty) ltd - cefotaxime sodium equiv. to cefotaxime - powder for injection - each vial contains cefotaxime sodium equiv. to cefotaxime 500 mg

Namibie - angličtina - Namibia Medicines Regulatory Council

bodene (pty) ltd - cefotaxime sodium equiv. to cefotaxime - powder for injection - each vial contains cefotaxime sodium equiv. to cefotaxime 1000mg

Namibie - angličtina - Namibia Medicines Regulatory Council

bodene (pty) ltd - cefotaxime sodium equiv. to cefotaxime - powder for injection - each vial contains cefotaxime sodium equiv. to cefotaxime 2,0 g

Spojené státy - angličtina - NLM (National Library of Medicine)

wyeth pharmaceuticals inc., a subsidiary of pfizer inc. - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - piperacillin anhydrous 2 g in 50 ml - zosyn is indicated for the treatment of patients with moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam-susceptible, β-lactamase producing strains of the designated microorganisms in the specified conditions listed below: appendicitis (complicated by rupture or abscess) and peritonitis caused by piperacillin-resistant, β‑lactamase producing strains of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis , b. ovatus , b. thetaiotaomicron , or b. vulgatus . the individual members of this group were studied in less than 10 cases. uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses, and ischemic/diabetic foot infections caused by piperacillin-resistant, β‑lactamase producing strains of staphylococcus aureus . postpartum endometritis or pelvic inflammatory disease caused by piperacillin-resistant, β‑lactamase producing strains of escherichia coli . community-acquired pneumonia (modera

Spojené státy - angličtina - NLM (National Library of Medicine)

mitim s.r.l. - piperacillin sodium (unii: m98t69q7hp) (piperacillin anhydrous - unii:9i628532gx), tazobactam sodium (unii: uxa545abtt) (tazobactam - unii:se10g96m8w) - piperacillin anhydrous 2 g in 10 ml - piperacillin and tazobactam for injection, usp is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a β-lactamase inhibitor, tazobactam, indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of the designated bacteria in the conditions listed below. appendicitis (complicated by rupture or abscess) and peritonitis caused by β-lactamase producing isolates of escherichia coli or the following members of the bacteroides fragilis group: b. fragilis , b. ovatus , b. thetaiotaomicron , or b. vulgatus . the individual members of this group were studied in fewer than 10 cases. uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by β-lactamase producing isolates of staphylococcus aureus . postpartum endometritis or pelvic inflammatory disease caused by β-lactamase producing isolates of escherichia coli . community-acquired pneumo